HYRIMOZ
Clinical safety rating: caution
Comprehensive clinical and safety monograph for HYRIMOZ (HYRIMOZ).
HYRIMOZ (adalimumab-adbm) is a tumor necrosis factor (TNF) blocker. It binds to TNF-alpha and neutralizes its activity, thereby reducing inflammation and immune responses mediated by TNF.
| Metabolism | Adalimumab-adbm is a monoclonal antibody; metabolism is not characterized as typical small molecule pathways. It is degraded into small peptides and amino acids via catabolic pathways, similar to endogenous immunoglobulins. |
| Excretion | Predominantly catabolized to amino acids; renal excretion of metabolites and unchanged drug is negligible (<1%). Biliary/fecal excretion of intact antibody is minimal (<0.1%). |
| Half-life | 11-17 days (mean ~14 days). The long half-life supports subcutaneous every-other-week dosing with potential dose interval adjustment in patients with high body weight or if trough levels are subtherapeutic. |
| Protein binding | Primarily binds to soluble and membrane-bound TNF-α; no significant binding to plasma proteins (albumin, alpha-1-acid glycoprotein) due to its antibody structure. Essentially unbound in circulation except when complexed with target. |
| Volume of Distribution | Approximately 0.1-0.2 L/kg (central compartment). The low Vd reflects distribution mainly within the vascular space and limited extravascular penetration due to large molecular size. This is consistent with monoclonal antibodies that do not extensively distribute into tissues. |
| Bioavailability | Subcutaneous: Absolute bioavailability approximately 64% (range 50-80%) compared with intravenous administration. |
| Onset of Action | Subcutaneous: clinical improvement in rheumatoid arthritis symptoms may be observed within 1-2 weeks, but maximal effect often requires 3-6 months of therapy. |
| Duration of Action | Subcutaneous: Suppression of TNF-α-mediated inflammation persists for approximately 2-4 weeks following a single dose. Trough levels remain above therapeutic threshold (≥5 μg/mL) with every-other-week dosing. |
Subcutaneous injection: 40 mg every other week, or 80 mg every other week in patients with inadequate response. For induction in ulcerative colitis: 160 mg on day 1, 80 mg on day 15, then 40 mg every other week.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for renal impairment. Safety and efficacy not established in severe renal disease. |
| Liver impairment | No dose adjustment recommended for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C). |
| Pediatric use | Approved for polyarticular juvenile idiopathic arthritis: weight ≥15 kg to <30 kg: 20 mg subcutaneously every other week; weight ≥30 kg: 40 mg subcutaneously every other week. For pediatric plaque psoriasis (≥4 years old) and pediatric uveitis (≥2 years old), dosing based on weight: 20 mg for <30 kg, 40 mg for ≥30 kg every other week. |
| Geriatric use | No specific dose adjustment required; use same as adult dosing. Monitor for infections and age-related comorbidities. Infections reported more frequently in patients ≥65 years. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for HYRIMOZ (HYRIMOZ).
| Breastfeeding | Adalimumab is excreted in breast milk in low amounts. M/P ratio not established. Limited data suggest no adverse effects in breastfed infants; however, systemic absorption is minimal. Use with caution, particularly in preterm or immunocompromised infants. |
| Teratogenic Risk | No evidence of teratogenicity in animal studies; human pregnancy registry data do not indicate increased risk of major birth defects. Theoretical risk of immune system suppression in the fetus, especially with exposure during second and third trimesters as IgG crosses the placenta. Live vaccines should be delayed in infants exposed in utero for at least 6 months. |
■ FDA Black Box Warning
WARNING: SERIOUS INFECTIONS and MALIGNANCY. Increased risk of serious infections leading to hospitalization or death, including tuberculosis, bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to opportunistic pathogens. Discontinue HYRIMOZ if a serious infection develops. Test for latent tuberculosis before and during therapy; treat latent infection prior to use. Malignancies, including lymphoma, have been reported in children and adolescents treated with TNF blockers.
| Serious Effects |
["Severe infections (e.g., active tuberculosis, sepsis, opportunistic infections)","Moderate to severe heart failure (NYHA class III/IV)"]
| Precautions | ["Serious infections including tuberculosis, bacterial sepsis, invasive fungal infections (e.g., histoplasmosis, coccidioidomycosis), and other opportunistic infections","Hepatitis B virus reactivation in chronic carriers","Demyelinating disease exacerbation or new onset (e.g., multiple sclerosis, optic neuritis)","Congestive heart failure worsening or new onset","Hematologic abnormalities including pancytopenia and aplastic anemia","Lupus-like syndrome","Hypersensitivity reactions including anaphylaxis","Vaccinations: avoid live vaccines during therapy"] |
Loading safety data…
| Fetal Monitoring | Monitor for maternal infections. In infants exposed in utero, monitor for infections and consider delaying live vaccinations for at least 6 months. No specific fetal monitoring required beyond routine prenatal care. |
| Fertility Effects | No evidence of impaired fertility in animal studies or human data. Adalimumab does not affect spermatogenesis or ovulation based on available evidence. |